KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Inventory: 2017-2025

Historic Inventory for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $614.5 million.

  • Amneal Pharmaceuticals' Inventory rose 3.04% to $614.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $614.5 million, marking a year-over-year increase of 3.04%. This contributed to the annual value of $612.5 million for FY2024, which is 5.34% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Inventory of $614.5 million as of Q3 2025, which was up 0.91% from $609.0 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Inventory's 5-year high stood at $614.5 million during Q3 2025, with a 5-year trough of $489.4 million in Q4 2021.
  • Its 3-year average for Inventory is $583.4 million, with a median of $581.4 million in 2023.
  • Examining YoY changes over the last 5 years, Amneal Pharmaceuticals' Inventory showed a top increase of 17.89% in 2021 and a maximum decrease of 0.26% in 2021.
  • Over the past 5 years, Amneal Pharmaceuticals' Inventory (Quarterly) stood at $489.4 million in 2021, then rose by 8.45% to $530.7 million in 2022, then grew by 9.54% to $581.4 million in 2023, then grew by 5.34% to $612.5 million in 2024, then increased by 3.04% to $614.5 million in 2025.
  • Its last three reported values are $614.5 million in Q3 2025, $609.0 million for Q2 2025, and $601.4 million during Q1 2025.